source
- Theravance, after clinical setbacks, agrees to $929M buyoutThe acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
- European regulators give second chance approval to Acadia’s Daybu for Rett syndromeEuropean Medicines Agency's CHMP has reversed its earlier negative vote and now recommends marketing authorization for Acadia Pharmaceuticals' drug Daybu (trofinetide) for Rett syndrome. The posit…